In addition to being adjuvant-free, the strengths of PBI’s vaccine regimens can be summarized as follows:
(1) DNA (in plasmid vector, as “prime”)
-
- Simple to manufacture at a relatively low cost and easy to produce on a mass scale
- Safe for human use with rare and mild adverse effects
- Easy to store with high stability
- Effective expression of HSP-linked viral fusion protein that is secreted and specifically recognized by antigen-presenting cells to induce robust immune responses without the need for adjuvants
(2) TA-HPV recombinant vaccinia virus (as “boost”)
-
- Replication-competent in host cells upon inoculation
- Well understood safety as this vector was administered globally
- Good transgene expression in antigen-presenting cells and intended immune responses
(3) TriGrid DNA delivery system
-
- Enhanced delivery of nucleic acid drug candidates
- Ease of use for clinical delivery of nucleic acid drugs
- Integrated and automated patented design
- Devices adapted for every stage of development from early non-clinical through commercial deployment